Helixgate

Helixgate

Uncategorized

Supreme Court restores access to abortion pill mifepristone through telehealth, mail, and pharmacies

WASHINGTON — The Supreme Court on Monday restored broad access to the abortion pill mifepristone, blocking a ruling that had threatened to upend one of the main ways abortion is provided across the nation.

The order signed by Justice Samuel Alito temporarily allows women seeking abortions to obtain the pill at pharmacies or through the mail, without an in-person visit to a doctor.

Read the rest…

Read More

Published

on

WASHINGTON — The Supreme Court on Monday restored broad access to the abortion pill mifepristone, blocking a ruling that had threatened to upend one of the main ways abortion is provided across the nation.

The order signed by Justice Samuel Alito temporarily allows women seeking abortions to obtain the pill at pharmacies or through the mail, without an in-person visit to a doctor.

Read the rest…

Read More

Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Uncategorized

FDA search for new CBER head focused on small group of final candidates

Published

on

The FDA has narrowed its search for a new leader of its Center for Biologics Evaluation and Research to three to four final candidates, according to a person familiar with the matter.

The agency hopes …

Continue Reading

Uncategorized

Celcuity strengthens case for ASCO-spotlighted breast cancer drug

The new data could support a broader approval submission for a therapy that is already under review and set to be showcased at the year’s biggest meeting for cancer research.

Read More

Published

on

The new data could support a broader approval submission for a therapy that is already under review and set to be showcased at the year’s biggest meeting for cancer research.

Read More

Continue Reading

Uncategorized

Passage cuts 75% of workforce after FDA trial design request

Published

on

Passage Bio, which has been working toward a registrational trial for a drug candidate whose indications include frontotemporal dementia, is exploring strategic alternatives in addition to cutting staff.

Continue Reading
Advertisement

Trending